A molecular investigation of true dominance in Huntington's disease

Journal of Medical Genetics

Volumn 36, Issue 10, 1999, Pages 739-746

  Narain, Yolanda ^a   Wyttenbach, Andreas ^a   Rankin, Julia ^a   Furlong, Robert A ^a   Rubinsztein, David C ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

CAG repeats; Huntingtin; Huntington's disease; True dominance

Indexed keywords

HUNTINGTIN; MUTANT PROTEIN; PROTEIN;

ALLELE; ANIMAL CELL; ARTICLE; CELL CULTURE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DOMINANT INHERITANCE; DOSE RESPONSE; EXON; GENE CONSTRUCT; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUNTINGTON CHOREA; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; PROTEIN AGGREGATION;

EID: 0032872817     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.36.10.739     Document Type: Article

References (41)

1. Ross CA, Hayden MR. Huntington's disease In: Rubinsztein DC, Hayden MR, eds. Analysis of triplet repeat disorders. Oxford: Bios Scientific, 1998:169-208.
2. Perutz MF. Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends Biochem Sci 1999;24:58-63.
3. Paulson HL. Protein fate in neurodegenerative proteinopathies: polyglutamine diseases join the (mis) fold. Am J Hum Genet 1999;64:339-45.
4. Rubinsztein DC, Wyttenbach A, Rankin J. Intracellular inclusions, pathological markers in diseases caused by expanded polyglutamine tracts? J Med Genet 1999;36:265-70.
5. Duyao MP, Auerbach AB, Ryan A, et al. Inactivation of the mouse Huntingdon's disease gene homolog Hdh. Science 1995;269:407-10.
6. Nasir J, Floresco SB, O'Kusky JR, et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995;81:811-23.
7. White JK, Auerbach W, Duyao MP, et al. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease GAG expansion, Nat Genet 1997;17:404-10.
8. Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 1995;11:155-63.
9. Becher MW, Kotzuk JA, Sharp AH, et al. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis 1997;4:1-11.
10. Davies SW, Turmaine M, Cozens BA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997;90:537-48.
11. Durr A, Hahn-Barm V, Brice A, Pecheux C, Dode C, Feingold J. Homozygosity in Huntington's disease. J Med Genet 1999;36:172-3.
12. Myers RH, Leavitt J, Farrer LA, et al. Homozygote for Huntingdon disease. Am J Hum Genet 1989;37:511-23.
13. Wexler NS, Young AB, Tanzi RE, et al. Homozygotes for Huntington disease. Nature 1987;326:194-7.
14. Goldfarb LG, Vasconcelos O, Platonov FA, et al. Unstable triplet repeat and phenotype variability of spinocerebellar ataxia type I. Ann Neurol 1996;39:500-6.
15. Matsumura R, Futamura N, Fujimot Y, et al. Spinocerebellar ataxia type 6. Molecular and clinical features of 35 Japanese patients including one homozygous for the GAG repeat expansion. Neurology 1997;49:1238-43.
16. Lerer I, Merims D, Abeliovich D, Zlotgora J, Gadoth N. Machado-Joseph disease: correlation between the clinical features, the CAG repeat length and homozygosity for the mutation. Eur J Hum Genet 1996;4:3-7.
17. Sanpei K, Takano H, Igarashi S, et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet 1996;14:277-84.
18. Sato K, Kashihara K, Okada S, et al. Does homozygosity advance the onset of dentato-rubral-pallidoluysian atrophy? Neurology 1995;45:1934-6.
19. Sobue G, Doyu M, Nakao N, et al. Homozygosity for Machado-Joseph disease gene enhances phenotypic severity. J Neurol Neurosurg Psychiatry 1996;60:354-6.
20. Cooper JK, Schilling G, Peters MF, et al. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet 1998;7:783-90.
21. Igarashi S, Koide R, Shimohata T, et al. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat Genet 1998;18:111-17.
22. Martindale D, Hackam A, Wieczorek A, et al. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet 1998;18:150-4.
23. Paulson HL, Perez MK, Trottier Y, et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 1997;19:333-44.
24. Li H, Li SH, Cheng AL, Mangiarini L, Bates GP, Li XJ. Ultrastructural localisation and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum Mol Genet 1999;8:1227-36.
25. Hackam AS, Singaraja R, Zhang T, Gan L, Hayden MR. In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease. Hum Mol Genet 1999;8:25-33.
26. Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998;95:55-66.
27. Klement IA, Skinner PJ, Kaytor MD, et al. Ataxin-1 nuclear localisation and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 1998;95:41-53.
28. Orr HT, Skinner PA, Klement CJ, Cummings CJ, Zoghbi HJ. The role of ataxin-1 nuclear expression and aggregates in SCA1 pathogenesis. Am J Hum Genet 1998;63(suppl):A8.
29. Perez MK, Paulson HL, Pendse SJ, Saionz SJ, Bonini NM, Pittman RN. Recruitment and the role of nuclear localisation in polyglutamine-mediated aggregation. J Cell Biol 1998;143:1457-70.
30. Snell RG, MacMillan JC, Cheadle JP, et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet 1993;4:393-7.
31. Farrer LA, Cupples LA, Wiater P, Conneally PM, Gusella JF, Myers RH. The normal HD allele, or a closely linked gene, influences the age at onset of Huntington disease. Am J Hum Genet 1993;53:125-30.
32. Burright EN, Clark HB, Servadio A, et al. SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 1995;82:937-48.
33. Reddy PH, Williams M, Charles V, et al. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet 1998;20:198-202.
34. Warrick JM, Paulson HL, Gray-Board GL, et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 1998;93:939-49.
35. Hodgson JG, Agopayan N, Gutekunst CA, et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999;23:181-92.
36. Coles R, Caswell R, Rubinsztein DC. Functional analysis of the Huntington's disease (HD) gene promoter. Hum Mol Genet 1998;7:791-800.
37. Lunkes A, Mandel JL. A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum Mol Genet 1998;7:1355-61.
38. Rubinsztein DC, Leggo J, Chiano M, et al. Genotypes at the GluR6 kinate receptor locus are associated with variation in the age of onset of Huntington disease. Proc Natl Acad Sci USA 1997;94:3872-6.
39. Scherzinger E, Sittler A, Schweiger K, et al. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc Natl Acad Sci USA 1999;96:4604-9.
40. N repeats in parent-offspring pairs with Huntington disease. Am J Hum Genet 1995;57:593-602.
41. Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 1997;60:1202-10.